HomeCompareGTH vs EQR

GTH vs EQR: Dividend Comparison 2026

GTH yields 49.69% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GTH wins by $347.3K in total portfolio value
10 years
GTH
GTH
● Live price
49.69%
Share price
$4.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$387.7K
Annual income
$78,189.68
Full GTH calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — GTH vs EQR

📍 GTH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGTHEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GTH + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GTH pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GTH
Annual income on $10K today (after 15% tax)
$4,223.60/yr
After 10yr DRIP, annual income (after tax)
$66,461.23/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, GTH beats the other by $63,214.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GTH + EQR for your $10,000?

GTH: 50%EQR: 50%
100% EQR50/50100% GTH
Portfolio after 10yr
$214.1K
Annual income
$41,004.64/yr
Blended yield
19.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

GTH
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-8.9
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GTH buys
0
EQR buys
0
No recent congressional trades found for GTH or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGTHEQR
Forward yield49.69%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$387.7K$40.5K
Annual income after 10y$78,189.68$3,819.61
Total dividends collected$308.9K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: GTH vs EQR ($10,000, DRIP)

YearGTH PortfolioGTH Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$15,669$4,968.94$11,248$547.57+$4.4KGTH
2$24,042$7,276.46$12,701$666.53+$11.3KGTH
3$36,160$10,434.49$14,405$814.59+$21.8KGTH
4$53,358$14,666.87$16,413$999.84+$36.9KGTH
5$77,320$20,226.76$18,795$1,232.92+$58.5KGTH
6$110,125$27,392.67$21,639$1,527.95+$88.5KGTH
7$154,296$36,462.43$25,057$1,903.80+$129.2KGTH
8$212,842$47,745.39$29,197$2,385.87+$183.6KGTH
9$289,294$61,553.22$34,250$3,008.70+$255.0KGTH
10$387,734$78,189.68$40,467$3,819.61+$347.3KGTH

GTH vs EQR: Complete Analysis 2026

GTHStock

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

Full GTH Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this GTH vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GTH vs SCHDGTH vs JEPIGTH vs OGTH vs KOGTH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.